Plus: costs vs outcomes; paying attention to young-onset patients; genetic dyslipidemia
April 25, 2020: Issue #1039 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
Lately my email has been full of information on the increased risk of death from Covid-19 if you have diabetes. There is evidently enough clamor that insulin companies are offering special discounts and free insulin to patients. I think that it is great, but why did it take an epidemic to make insulin prices go down? More importantly, will they go back up when the pandemic is over?
This points out the dilemma that many medical professionals face when they manage complex patients. This week we have part 2 of our series, on Cost Vs Outcomes, that delves into why medication prices are so high.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
|
Doctor's Option lab test products include rapid tests and CLIA certified fingerstick lab tests.
Rapid tests offer immediate test results to provide doctors with point of care test results in as little as 90 seconds.
Fingerstick lab tests provide CLIA certified lab accurate results. Each fingerstick lab test collection kit comes with a prepaid postage return envelope and everything you need to obtain and collect your fingerstick blood sample in a 510K FDA approved device.
Fingerstick lab tests are great for people who want to monitor their blood sugar, cholesterol, lipids and other important bio-markers at home or on the go.
Visit Doctor's Option |
|
|
|
|
TOP STORIES - Diabetes News and Research |
|
| How To Overcome The Complexities of Treatment Decisions For Patients With Type 2 Diabetes, Part 2
Costs vs. Outcomes for Patients With Type 2 Diabetes: The issue of cost in healthcare is a central point in the discussion of the future of medicine. While much is made of the cost of end-of-life care, many of the dollars spent yearly are focused on the treatment of chronic diseases like diabetes. The estimated yearly cost of diabetes care was $245 billion in the U.S. in 2012, the last year for which numbers have been reported. $50 billion of that was related to prescription drug purchases. |
| |
|
|
How Diabetes Cost Is Directly Related To A1c
Have you ever paid attention to the cost of a box of diabetic test strips? Poor management of type 2 diabetes can cost a person with diabetes thousands of dollars; it costs less to pay attention to your health. |
| |
|
|
|
|
| Did You Know? Why More Attention Needs to Be Provided to Those with Young-Onset Diabetes:
The prevalence of type 2 diabetes is increasing among adults under age 45. The onset of type 2 diabetes at a younger age increases an individual’s risk for diabetes-related complications. Given the lasting benefits conferred by early glycemic control, this study compared glycemic control and initial care between adults with younger-onset (21–44 years) and mid-age onset (45–64 years) of type 2 diabetes. Using data from an extensive, integrated health care system, they identified 32,137 adults (aged 21–64 years) with incident diabetes (first HbA1c ≥6.5% [≥48 mmol/mol]). Anyone with evidence of prior type 2 diabetes, gestational diabetes, or type 1 diabetes was excluded. Of identified individuals, 26.4% had younger-onset, and 73.6% had mid-age onset type 2 diabetes. Adults with younger-onset had higher initial mean HbA1c values (8.9% [74 mmol/mol]) than adults with onset in mid-age (8.4% [68 mmol/mol]) (P < 0.0001) and lower odds of achieving an HbA1c <7% (<53 mmol/mol) 1 year after the, even after accounting for HbA1c at diagnosis. Adults with younger-onset had lower odds of in-person primary care contact than those with onset during mid-age, but they did not differ in telephone contact. Adults with younger-onset had higher odds of starting metformin, but lower odds of adhering to that medication. From the results, it was concluded that adults with the onset of type 2 diabetes at a younger age were less likely to achieve glycemic control at one year following diagnosis, suggesting the need for tailored care approaches to improving outcomes for this high-risk patient population. Diabetes Care |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Deonna Andrews, PharmD Candidate 2020 of Florida Agricultural & Mechanical University College of Pharmacy and Pharmaceutical Sciences Mia Flowers, PharmD. Candidate of Florida Agricultural & Mechanical University School of Pharmacy Mit Suthar, PharmD. Candidate, LECOM School of Pharmacy Chardae Whitner PharmD Candidate L|E|C|O|M Bradenton School of Pharmacy |
|
|
|
|
|
| | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
